A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone (M), etoposide (E), and the MDR modulator PSC833: Southwest Oncology Group Study #9617.

被引：0
|
作者：
Chauncey, TR
Rankin, C
Anderson, JE
Godwin, JA
Kalaycio, M
Moore, DF
Petersdorf, SH
Shurafa, MS
Kraut, EH
Head, DR
Slovak, ML
Willman, CL
Appelbaum, FR
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Canc Ctr Kansas, Wichita, KS USA
[5] Henry Ford Hosp, Detroit, MI 48202 USA
[6] Puget Sound Oncol Consortium, Seattle, WA USA
[7] Ohio State Univ, Columbus, OH 43210 USA
[8] SW Oncol Grp, Seattle, WA USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
945
引用
收藏
页码：231A / 231A
页数：1
相关论文
共 37 条
  • [1] A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617
    Chauncey, TR
    Rankin, C
    Anderson, JE
    Chen, IM
    Kopecky, KJ
    Godwin, JE
    Kalaycio, ME
    Moore, DF
    Shurafa, MS
    Petersdorf, SH
    Kraut, EH
    Leith, CP
    Head, DR
    Luthardt, FW
    Willman, CL
    Appelbaum, FR
    LEUKEMIA RESEARCH, 2000, 24 (07) : 567 - 574
  • [2] A phase I dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine (PSC-MEC) in poor prognosis acute leukemia (AML).
    Visani, G
    Milligan, D
    Leoni, F
    Chang, J
    Kelsey, S
    Marcus, R
    Powles, R
    Schey, S
    Covelli, A
    BLOOD, 1997, 90 (10) : 2518 - 2518
  • [3] A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and leukemia group B (CALGB) study 9420.
    Lee, E
    George, S
    Caligiuri, M
    Dodge, R
    Smith, R
    Szatrowski, T
    Schiffer, C
    BLOOD, 1997, 90 (10) : 2256 - 2256
  • [4] Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
    Anderson, JE
    Kopecky, KJ
    Willman, CL
    Head, D
    O'Donnell, MR
    Luthardt, FW
    Norwood, TH
    Chen, IM
    Balcerzak, SP
    Johnson, DB
    Appelbaum, FR
    BLOOD, 2002, 100 (12) : 3869 - 3876
  • [5] Dose finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ARA-C in untreated elderly patients with acute myeloid leukaemia (AML).
    Sonneveld, P
    Lowenberg, B
    Vossebeld, P
    Malkhandi, J
    Covelli, A
    Dekker, AW
    Ossenkoppele, G
    Milligan, D
    Verhoef, G
    Ferrant, A
    Yin, J
    Gratwohl, A
    Kovacsovics, T
    Burnett, A
    BLOOD, 1997, 90 (10) : 2517 - 2517
  • [6] Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Swaminathan, Mahesh
    Przespolewski, Amanda
    Griffiths, Elizabeth A.
    Thompson, James E.
    Elshoury, Amro
    Walinski, Wendy
    Wang, Eunice S.
    BLOOD, 2021, 138
  • [7] Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group
    O'Brien, Maureen M.
    Lacayo, Norman J.
    Lum, Bert L.
    Kshirsagar, Smita
    Buck, Steven
    Ravindranath, Yaddanapudi
    Bernstein, Mark
    Weinstein, Howard
    Chang, Myron N.
    Arceci, Robert J.
    Sikic, Branimir I.
    Dahl, Gary V.
    PEDIATRIC BLOOD & CANCER, 2010, 54 (05) : 694 - 702
  • [8] A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
    Gruber, A
    Björkholm, M
    Brinch, L
    Evensen, S
    Gustavsson, B
    Hedenus, M
    Juliusson, G
    Löfvenberg, E
    Nesthus, I
    Simonsson, B
    Sjo, M
    Stenke, L
    Tangen, JM
    Tidefelt, U
    Udén, AM
    Paul, C
    Liliemark, J
    LEUKEMIA RESEARCH, 2003, 27 (04) : 323 - 328
  • [9] A randomized, phase III trial of mitoxantrone (M) plus etoposide (E) versus daunomycin (D) plus cytarabine (A) as induction therapy in patients over age 55 with previously untreated acute myeloid leukemia (AML): Southwest oncology group study 9333.
    Anderson, JE
    Kopecky, KJ
    Head, D
    O'Donnell, MR
    Luthardt, FW
    Norwood, TH
    Willman, CL
    Balcerzak, SP
    Johnson, DB
    Appelbaum, FR
    BLOOD, 1999, 94 (10) : 383A - 383A
  • [10] Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    BLOOD, 2002, 100 (04) : 1224 - 1232
1234